841 related articles for article (PubMed ID: 31423560)
21. Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases.
Castelino FV; Moua T
ACR Open Rheumatol; 2021 May; 3(5):295-304. PubMed ID: 33779080
[TBL] [Abstract][Full Text] [Related]
22. Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.
Wongkarnjana A; Scallan C; Kolb MRJ
Curr Opin Pulm Med; 2020 Sep; 26(5):436-442. PubMed ID: 32657838
[TBL] [Abstract][Full Text] [Related]
23. Progressive pulmonary fibrosis in systemic autoimmune diseases. A real life study.
Durán Barata D; Jaureguizar Oriol A; Loarce Martos J; Morell Hita JL; de la Puente Bujidos C; Rigual Bobillo J
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):211-214. PubMed ID: 37005131
[TBL] [Abstract][Full Text] [Related]
24. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
[TBL] [Abstract][Full Text] [Related]
25. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
26. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
Hoffmann-Vold AM; Weigt SS; Saggar R; Palchevskiy V; Volkmann ER; Liang LL; Ross D; Ardehali A; Lynch JP; Belperio JA
EBioMedicine; 2019 Dec; 50():379-386. PubMed ID: 31732480
[TBL] [Abstract][Full Text] [Related]
27. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].
Buschulte K; Hoffmann-Vold AM; Dobrota RD; Höger P; Krause A; Kreuter M
Z Rheumatol; 2021 Oct; 80(8):743-754. PubMed ID: 34505934
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Approach to Adult Fibrotic Lung Diseases.
Adegunsoye A; Strek ME
Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
[TBL] [Abstract][Full Text] [Related]
30. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
[No Abstract] [Full Text] [Related]
31. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.
Matteson EL; Aringer M; Burmester GR; Mueller H; Moros L; Kolb M
Clin Rheumatol; 2023 Sep; 42(9):2311-2319. PubMed ID: 37209188
[TBL] [Abstract][Full Text] [Related]
32. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis.
Marigliano B; Soriano A; Margiotta D; Vadacca M; Afeltra A
Autoimmun Rev; 2013 Sep; 12(11):1076-84. PubMed ID: 23684699
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
Collins BF; Luppi F
Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
[TBL] [Abstract][Full Text] [Related]
34. The evolving pharmacotherapy of pulmonary fibrosis.
Lota HK; Wells AU
Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
[TBL] [Abstract][Full Text] [Related]
35. Progressive fibrotic interstitial lung disease.
Pereira CAC; Cordero S; Resende AC
J Bras Pneumol; 2023; 49(5):e20230098. PubMed ID: 37610955
[TBL] [Abstract][Full Text] [Related]
36. Acute exacerbations of progressive-fibrosing interstitial lung diseases.
Kolb M; Bondue B; Pesci A; Miyazaki Y; Song JW; Bhatt NY; Huggins JT; Oldham JM; Padilla ML; Roman J; Shapera S
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578331
[TBL] [Abstract][Full Text] [Related]
37. Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be.
Goos T; De Sadeleer LJ; Yserbyt J; Verleden GM; Vermant M; Verleden SE; Wuyts WA
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807034
[TBL] [Abstract][Full Text] [Related]
38. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
Nili M; Singer D; Hanna M
BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
[TBL] [Abstract][Full Text] [Related]
39. Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications.
Erre GL; Sebastiani M; Manfredi A; Gerratana E; Atzeni F; Passiu G; Mangoni AA
Drugs Context; 2021; 10():. PubMed ID: 33505482
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms and management of cough in interstitial lung disease.
Rasheed AZ; Metersky ML; Ghazal F
Expert Rev Respir Med; 2023 Dec; 17(12):1177-1190. PubMed ID: 38159067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
